ArticleTherapeutic advances in medical oncology2026
Primary prostatic seminoma: a rare case report and structured literature review highlighting tumor marker discordance.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary prostatic seminoma (PPS) is an exceptionally rare extragonadal germ cell tumor, with only isolated cases reported in the literature. Owing to its anatomical location, PPS may clinically and radiologically mimic prostate adenocarcinoma or other bulky pelvic malignancies, creating a risk of inappropriate local treatment. We report the case of a 34-year-old man presenting with a large prostatic mass and discordance between substantial tumor burden and only mildly elevated serum prostate-specific antigen (PSA; 3.43 µg/L). Serum lactate dehydrogenase (LDH) was markedly elevated (11.50 µkat/L), beta-human chorionic gonadotropin (beta-hCG) was mildly increased (5.3 IU/L), and alpha-fetoprotein remained within the normal range. Multiparametric magnetic resonance imaging and [18F]FDG positron emission tomography/computed tomography demonstrated a bulky, metabolically active prostatic tumor, but histopathological verification was essential for diagnosis. Immunohistochemistry showed strong positivity for SALL4 and c-KIT/CD117 with focal placental alkaline phosphatase expression, and negativity for prostatic, lymphoid, and non-seminomatous germ cell tumor markers, confirming seminoma. The patient was classified as good-risk according to the International Germ Cell Cancer Collaborative Group classification and achieved sustained complete remission following cisplatin-based chemotherapy. A structured literature review following PRISMA reporting principles identified 12 modern cases reported between 1990 and 2026. A recurrent observation was biochemical discordance between extensive tumor burden and low or only mildly elevated serum PSA levels. Germ cell markers, including LDH and beta-hCG, were variably elevated but lacked sufficient sensitivity and specificity to establish or exclude the diagnosis. Most patients were treated with cisplatin-based chemotherapy and/or radiotherapy, with a high rate of complete remission. PPS is a rare but highly curable malignancy. In young patients with atypical bulky prostatic masses and PSA levels disproportionate to tumor burden, early biopsy with germ cell-specific immunohistochemistry is essential. Functional imaging may support staging and response assessment, but systemic cisplatin-based chemotherapy remains the cornerstone of curative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.